Paragh, György
https://orcid.org/0000-0002-6612-9267
Mayo Clinic
Roswell Park Comprehensive Cancer Center
Citations 2
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad, Amini, Arya , Bibee, Kristin , Bolotin, Diana, DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , LeBoeuf, Nicole R. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Paragh, György , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Sharma, Bhavina, Sokumbi, Yemi, Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Bordeaux, Jeremy S. , Chen, Pei-Ling , Contreras, Carlo M. , Donigan, Jessica M. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Sharma, Bhavina, Srivastava, Divya , Yusuf, Mehran Behruj
Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.
Clinical Utility of a Digital Dermoscopy Image-Based Artificial Intelligence Device in the Diagnosis and Management of Skin Cancer by Dermatologists
Witkowski, Alexander , Burshtein, Joshua , Cockerell, Clay J. , Correa‐Selm, Lilia , Cotter, David G. , Ellis, Darrell L., Farberg, Aaron S. , Grant-Kels, Jane M, Greiling, Teri M. , Grichnik, James M. , Leachman, Sancy A. , Linfante, Anthony , Marghoob, Ashfaq A. , Paragh, György , Rabinovitz, Harold , Rigel, Darrell S. , Siegel, Daniel M. , Song, Eingun James , Swanson, David C. , Trask, David, Łudzik, Joanna , Correa, Lilia , Greiling, Teri M , Grichnik, James M , Leachman, Sancy A , Paragh, Gyorgy , Siegel, Daniel M , Song, Eingun James , Swanson, David, Ludzik, Joanna , Christopher, Michael, Ellis, Darrell L., Grant-Kels, Jane Margaret , Marks, Etan , Nguyen, Khoa, Ortega‐Loayza, Alex G. , Pellacani, Giovanni , Trask, David
Cancers | October 25, 2024 | Volume: 16 | Issue: 21 | Pages: 3592
Background: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. Objective: To evaluate the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm (DDI-AI device) on the diagnosis and management of skin cancers by dermatologists. Methods: Thirty-six United States board-certified dermatologists evaluated 50 clinical images and 50 digital dermoscopy images of the same skin lesions (25 malignant and 25 benign), first without and then with knowledge of the DDI-AI device output. Participants indicated whether they thought the lesion was likely benign (unremarkable) or malignant (suspicious). Results: The management sensitivity of dermatologists using the DDI-AI device was 91.1%, compared to 84.3% with DDI, and 70.0% with clinical images. The management specificity was 71.0%, compared to 68.4% and 64.9%, respectively. The diagnostic sensitivity of dermatologists using the DDI-AI device was 86.1%, compared to 78.8% with DDI, and 63.4% with clinical images. Diagnostic specificity using the DDI-AI device increased to 80.7%, compared to 75.9% and 73.6%, respectively. Conclusion: The use of the DDI-AI device may quickly, safely, and effectively improve dermoscopy performance, skin cancer diagnosis, and management when used by dermatologists, independent of training and experience.